首页> 美国卫生研究院文献>BMC Clinical Pharmacology >The world's first clinical randomized trial of atrial natriuretic peptide for preventing cancer recurrence following lung cancer surgery
【2h】

The world's first clinical randomized trial of atrial natriuretic peptide for preventing cancer recurrence following lung cancer surgery

机译:心房利钠肽预防肺癌手术后癌症复发的全球首例临床随机试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Most patients suffering from cancer die of metastatic disease. Surgical removal of solid tumors is performed as an initial attempt to cure patients if the primary tumor meets surgical indications. However, it is possible that surgical trauma itself influences the development of early recurrence. First, resection handling of the tumor can provoke detachment of tumor cells. Second, surgical trauma provokes the severe inflammatory reaction. Vascular inflammation is considered to render the endothelium adhesive to circulating tumor cells thereby allowing the metastasis of tumor cells. We have previously reported that administration of atrial natriuretic peptide (ANP) during the perioperative period reduces inflammatory response and has a prophylactic effect on postoperative cardiopulmonary complications in lung cancer surgery. Here we demonstrate that cancer recurrence after curative surgery was significantly lower in ANP-treated patients than in control patients (surgery alone). ANP is known to bind specifically to guanylyl cyclase-A (GC-A) receptor. In mouse models, we found that metastasis of GC-A–non-expressing tumor cells (i.e., B16 mouse melanoma cells) to the lung was increased in vascular endothelium-specificGC-A knockout mice and decreased in vascular endothelium-specific GC-A transgenic mice compared with control mice. ANP inhibited the adhesion of cancer cells to human pulmonary artery endothelial cells by suppressing the E-selectin expression that is promoted by inflammation. These results suggest that ANP prevents cancer metastasis by inhibiting the adhesion of tumor cells to inflamed endothelial cells. Thus, we have planned to start a multicenter randomized clinical trial to examine the use of perioperative administration of ANP for the prevention of cancer recurrence after lung cancer surgery in this year. In the near future, we want to expand the adaptation of ANP for various types of cancer surgery.
机译:大多数患有癌症的患者死于转移性疾病。如果原发肿瘤符合手术指征,则通过手术切除实体瘤是治愈患者的最初尝试。但是,手术创伤本身可能会影响早期复发的发展。首先,肿瘤的切除处理可引起肿瘤细胞脱离。其次,外科创伤引起严重的炎症反应。血管炎症被认为使内皮粘附于循环的肿瘤细胞,从而允许肿瘤细胞的转移。我们以前曾报道过,在围手术期给予心房利钠肽(ANP)可以减少炎症反应,并对肺癌手术后的心肺并发症具有预防作用。在这里,我们证明,在接受ANP治疗的患者中,根治性手术后的癌症复发率明显低于对照组(仅手术)。已知ANP与鸟苷酸环化酶A(GC-A)受体特异性结合。在小鼠模型中,我们发现,不表达GC-A的肿瘤细胞(即B16小鼠黑色素瘤细胞)向肺的转移在血管内皮特异性GC-A基因敲除小鼠中增加,而在血管内皮特异性GC-A中减少转基因小鼠与对照小鼠相比。 ANP通过抑制炎症促进的E-选择素表达来抑制癌细胞对人肺动脉内皮细胞的粘附。这些结果表明,ANP通过抑制肿瘤细胞与发炎的内皮细胞的粘附来预防癌症转移。因此,我们计划在今年开始一项多中心随机临床试验,以检查围手术期使用ANP预防肺癌手术后癌症复发的用途。在不久的将来,我们希望扩大ANP对各种类型的癌症手术的适应性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号